MASH - Metabolic Dysfunction-Associated Steatohepatitis
16
13
13
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 16 trials
19%
3 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (16)
Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
Fructose is a Metabolic and Inflammatory Pathogenic Factor in Metabolic Dysfunction-associated Steatohepatitis (MASH)
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Time-restricted Eating and Healthy Eating in Patients With Metabolic Liver Disease or Cancer
A Phase 3 Study Evaluating the Safety and Efficacy of HSK31679 in Patients With MASH
Diagnostic Value of the Liver Inflammation Index for MASH in Patients With T2DM and MAFLD
A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus
Digoxin In NASH (CODIN)
Study of TGM-312-SC01 in Healthy Participants and Adults With MASH
A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)
Rezdiffra Pregnancy and Lactation Registry
Exercise for an Aging Liver (EXALIVER)
High-Risk Transcriptome Molecular Prediction Study of MASH-Associated Colorectal Polyps
Betaine vs. Placebo for Serologically Diagnosed Metabolic Dysfunction-associated Steatohepatitis (MASH)
Resmiterom Efficacy & Safety in Patients With MASH
Evaluation of a New Ultrasound System for the Non-invasive Assessment of Liver Steatosis in MASLD/MASH Patients